Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States.Am J Kidney Dis2005; 45 (Suppl. 1Il calciomimetico nell'iperparatiroidismo primitivo e se): A5–7, S1–280.
2.
LocatelliF., BommerJ., LondonG.M.. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment.Nephrol Dial Transplant2001; 16: 459–68.
3.
GoodmanW.G., GoldinJ., KuizonB.D.. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.N Engl J Med2000; 342: 1478–83.
4.
GaneshS.K., StackA.G., LewinN.W.. Association of elevated serum PO(4),CaPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.J Am Soc Nephrol2001; 12: 2131–8.
5.
BlockG.A., KlassenP., LazarusJ.M.. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.J Am Soc Nephrol2004; 15: 2208–18.
6.
KestenbaumB., SampsonJ.N., RudserK.D.. Serum phosphate levels and mortality risk among people with chronic kidney disease.J Am Soc Nephrol2005; 16: 520–8.
7.
Rodriguez BenotA., Martin MaloA., Alvarez LaraM.A., RodriguezM., AjamaP.Mild hyperphosphatemia and mortality in hemodialysis patients.Am J Kidney Dis2005; 46(1Il calciomimetico nell'iperparatiroidismo primitivo e se): 68–77.
8.
Kalantar ZadehK., KuwaeN., RegidorD.L.. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.Kidney Int2006; 70(4): 771–80.
9.
WolfM., ShahA., GutierrezO.. Vitamin D levels and early mortality among incident hemodialysis patients.Kidney Int2007; 72(8): 1004–13.
10.
RavaniP., MalbertiF., TripepiG.. Vitamin D levels and patients outcome in chronic kidney disease.Kidney Int2009; 75: 88–95.
11.
National Kidney Foundation: Bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42 (Suppl. 3): S1–202.
12.
TentoriF., BlayneyM.J., AbertJ.M.. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus and PTH: the Dialysis and Practice Pattern Study (DOPPS).Am J Kidney Dis2008; 52: 519–30.
13.
BlockG.A., MartinK.J., De FranciscoA.L.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.N Engl J Med2004; 8: 350 (15): 1516–25.
14.
LindbergJ.S., CulletonB., WongG.. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind multicenter study.J Am Soc Nephrol2005; 16: 800–07.
15.
MoeS., ChertowG.M., CoburnJ.W.. Achieving NFKK/DOQI bone metabolism and disease treatment goals with Cinacalcet HCl.Kidney Int2005; 67: 760–71.
16.
GoodmanW.G., FaddaG.Z., FilkelsteinF.O.. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (HPT).J Am Soc Nephrol2003; 14: 460A, SA-PO741.
17.
ChertowG.M., BlumenthalS., TurnerS.. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivates with controlled PTH and elevated calcium and phosphorus.Clin J Am Soc Nephrol2006; 1(2): 305–12.
18.
MessaP., MacarioF., YaqoobM.. The OPTIMA study: assessing a new cinacalcet (Mimpara®/Sensipar®) treatment algorithm for secondary hyperparathyroidism.Clin J Am Soc Nephrol2008; 3: 36–45.
19.
MoeS.M., GoodmanW.G., CunninghamJ.. Cinacalcet HCl sustains long-term control of secondary hyperparathyroidism.Nephrol Dial Transplant2005; 16: 501A, F-PO755.
20.
MoeS.M., CunninghamJ., BrommerJ.. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.Nephrol Dial Transplant2005; 20: 2168–93.
21.
ChoncholM., LocatelliF., AbboudH.E.. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Cinacalcet HCl in participants with CKD not receiving dialysis.Am J Kidney Dis2009; 53: 197–207.
22.
EvenepoelP., ClaesK., KuypersD.R., DebruyneF., VanrenterghemY.Parathyroidectomy after successful kidney transplantation: a single centre study.Nephrol Dial Transplant2007; 22: 1730–7.
23.
EvenepoelP., ClaesK., KuypersD., MaesB., BammensB., VanrenterghemY.Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.Nephrol Dial Transplant2004; 19: 1281.
24.
KruseA.E., EisenbergerU., FreyF.J., MohauptM.G.The calcimimetic Cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.Nephrol Dial Transplant2005; 20: 1311–4.
25.
SerraA.L., SchwarzA.A., WickF.H.. Successful treatment of hypercalcemia with Cinacalcet in renal transplant recipients with persistent hyperparathyroidism.Nephrol Dial Transplant2005; 20: 1315–9.
26.
SzwarcI., ArgilésA., GarrigueV.. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.Transplantation2006; 82: 675–80.
27.
PeacockM., BilezikianJ.P., KlassenP.S.. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.J Clin Endocrinol Metab2005; 90(1Il calciomimetico nell'iperparatiroidismo primitivo e se): 135–41.
28.
PeacockM., ScumpiaS., BologneseM.A.. Long-term control of primary hyperparathyroidism with cinacalcet.J Bone Miner Res2006; 21(Suppl 1Il calciomimetico nell'iperparatiroidismo primitivo e se): S38.
29.
SilverbergS.J., FaimanC., BilezikianJ.P.. The effects of Cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary hyperparathyroidism after parathyroidectomy.J Bone Miner Res2003; 18: 171.
